GOLDEN BIOTECHNOLOGY CORP.
Booth No: L632A
Golden Biotechnology Corp.,leading pharma in cancer and other new drugs . Received Orphan Drug Designations by US FDA for Pancreatic Cancer, AML and HCC and Pancreatic Cancer by EU EMA. Completed first stage of Phase II trial of NSCLC and will release in 2019 ASCO meeting.Winner of the Advance Queensland - Johnson & Johnson Innovation QuickFire Challenge in Alzheimer's Disease study in 2016. In 2018 , successful unblinding on clinical trial of hyperlipidemia. Welcome visit us at L 632A.
Exhibitor Press Release
- GoldenBiotech Antroquinonol Phase 2 NSCLC Study Presents Brilliant Results in ASCO Meeting 2019-05-20
Exhibitors you may be interested in